Literature DB >> 7634602

Tumor-bone interactions in skeletal metastasis.

F W Orr1, O H Sanchez-Sweatman, P Kostenuik, G Singh.   

Abstract

Bone metastases are a frequent clinical problem in patients with breast, prostate, and other cancers. Formation of these lesions is a site-specific process determined by multiple cellular and molecular interactions between the cancer cells and the bone microenvironment. Clinical studies, and in vivo and in vitro experimental approaches, have been useful to dissect different stages of this process. Mechanisms identified as relevant to cancer spreading and tumoral growth in the bones include (a) early vascular spread of cancer cells to bones; (b) adhesion of cancer cells to the bone microvasculature and matrix components; (c) presence of growth factors and chemo-attractants in bone; (d) osteolysis by osteoclasts, tumor associated macrophages, and cancer cells; and (e) tumor-induced local osteoblastic proliferation. Although none of these mechanisms alone are responsible for the development of bone metastases, their investigation may lead to novel therapeutic approaches that specifically block these stages and, thus, may hinder development of bone metastasis. The use of bisphosphonates and other experimental strategies already is being tested in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7634602

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  14 in total

1.  Partial purification of a liver-derived tumor cell growth inhibitor that differentially inhibits poorly-liver metastasizing cell lines: identification as an active subunit of arginase.

Authors:  P G Cavanaugh; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Chemical inhibitors of the calcium entry channel TRPV6.

Authors:  Christopher P Landowski; Katrin A Bolanz; Yoshiro Suzuki; Matthias A Hediger
Journal:  Pharm Res       Date:  2010-11-06       Impact factor: 4.200

Review 3.  The Yin and Yang of bone morphogenetic proteins in cancer.

Authors:  Ashok Singh; Rebecca J Morris
Journal:  Cytokine Growth Factor Rev       Date:  2010-08-04       Impact factor: 7.638

4.  Transforming growth factor beta upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen.

Authors:  P J Kostenuik; G Singh; F W Orr
Journal:  Clin Exp Metastasis       Date:  1997-01       Impact factor: 5.150

Review 5.  BMPs and their clinical potentials.

Authors:  Meejung Kim; Senyon Choe
Journal:  BMB Rep       Date:  2011-10       Impact factor: 4.778

6.  Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells.

Authors:  Dominik Rüttinger; Rui Li; Walter J Urba; Bernard A Fox; Hong-Ming Hu
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and Disease.

Authors:  Xu Feng
Journal:  Curr Chem Biol       Date:  2009-05-01

Review 8.  Molecular mechanisms of metastasis in prostate cancer.

Authors:  Noel W Clarke; Claire A Hart; Mick D Brown
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

9.  Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.

Authors:  Kyle G Halvorson; Molly A Sevcik; Joseph R Ghilardi; Lucy J Sullivan; Nathan J Koewler; Frieder Bauss; Patrick W Mantyh
Journal:  J Pain Symptom Manage       Date:  2008-04-14       Impact factor: 3.612

10.  Loss of P53 facilitates invasion and metastasis of prostate cancer cells.

Authors:  Yi Wang; Y X Zhang; C Z Kong; Z Zhang; Y Y Zhu
Journal:  Mol Cell Biochem       Date:  2013-08-28       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.